Comparative Pharmacology
Head-to-head clinical analysis: E MYCIN E versus ZITHROMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E MYCIN E versus ZITHROMAX.
E-MYCIN E vs ZITHROMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptide chains.
Azithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by preventing translocation of peptides. It also has immunomodulatory and anti-inflammatory effects.
250-500 mg orally every 6 hours or 333-500 mg every 8 hours; maximum 4 g/day.
500 mg orally once daily for 3 days, or 2 g orally as a single dose for certain infections.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Terminal elimination half-life of approximately 68 hours (range 35-96 hours), allowing once-weekly dosing for some indications.
Primarily excreted unchanged in urine (70-80%) via glomerular filtration and tubular secretion; 15-20% excreted in feces via biliary elimination.
Primarily eliminated via biliary/fecal route (∼50-60% as unchanged drug); renal excretion accounts for ∼12% of the dose; minimal metabolism.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic